DPD variants

Pharmacogenetic Biomarker

DPD variants

Selected Variants (Mutant Allele, Enzyme Activity)

DPYD*2A (1905+1G>A, none);

DPYD*13 (1679T>G, ↓↓);

DPYD rs67376798 (2846A>T, ↓↓)

Allele Frequency

These non-functional variants are present in 0.1–1% of whites (eg, French Caucasians)

Drugs

5-fluorouracil (5-FU), capecitabine (Xeloda)

Clinical Relevance

Fluoropyrimidines (ie, 5-fluorouracil, capecitabine) are metabolized by dihydropyrimidine dehydrogenase (DPD) enzyme, encoded by the DPYD gene. To avoid severe or even fatal drug toxicity, an alternative drug should be selected for patients who are homozygous for DPYD non-functional variants (*2A, *13, or rs67376798). Consider a 50% reduction in starting dose for heterozygous patients who have low DPD activity (30–70% of normal).

DPD variants is a sample topic from the Guide to Diagnostic Tests.

To view other topics, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Complete Product Information.